CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8+ T Cells
©2017 American Association for Cancer Research..
The ability of CD8+ T lymphocytes to eliminate tumors is limited by their ability to engender an immunosuppressive microenvironment. Here we describe a subset of tumor-infiltrating CD8+ T cells marked by high expression of the immunosuppressive ATP ecto-nucleotidase CD39. The frequency of CD39highCD8+ T cells increased with tumor growth but was absent in lymphoid organs. Tumor-infiltrating CD8+ T cells with high CD39 expression exhibited features of exhaustion, such as reduced production of TNF and IL2 and expression of coinhibitory receptors. Exhausted CD39+CD8+ T cells from mice hydrolyzed extracellular ATP, confirming that CD39 is enzymatically active. Furthermore, exhausted CD39+CD8+ T cells inhibited IFNγ production by responder CD8+ T cells. In specimens from breast cancer and melanoma patients, CD39+CD8+ T cells were present within tumors and invaded or metastatic lymph nodes, but were barely detectable within noninvaded lymph nodes and absent in peripheral blood. These cells exhibited an exhausted phenotype with impaired production of IFNγ, TNF, IL2, and high expression of coinhibitory receptors. Although T-cell receptor engagement was sufficient to induce CD39 on human CD8+ T cells, exposure to IL6 and IL27 promoted CD39 expression on stimulated CD8+ T cells from human or murine sources. Our findings show how the tumor microenvironment drives the acquisition of CD39 as an immune regulatory molecule on CD8+ T cells, with implications for defining a biomarker of T-cell dysfunction and a target for immunotherapeutic intervention.Significance: The tumor microenvironment elicits a subset of functionally exhausted CD8+ T cells by creating conditions that induce cell surface expression of CD39, an immunosuppressive molecule that can be therapeutically targeted to restore effector T-cell function. Cancer Res; 78(1); 115-28. ©2017 AACR.
| Errataetall: |
CommentIn: Cancer Res. 2018 Sep 1;78(17):5173-5174. - PMID 30115699 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
Cancer research - 78(2018), 1 vom: 01. Jan., Seite 115-128 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Canale, Fernando P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
8L70Q75FXE |
|---|
| Anmerkungen: |
Date Completed 05.11.2018 Date Revised 03.01.2021 published: Print-Electronic CommentIn: Cancer Res. 2018 Sep 1;78(17):5173-5174. - PMID 30115699 Citation Status MEDLINE |
|---|
| doi: |
10.1158/0008-5472.CAN-16-2684 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM277347734 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM277347734 | ||
| 003 | DE-627 | ||
| 005 | 20231225014017.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/0008-5472.CAN-16-2684 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0924.xml |
| 035 | |a (DE-627)NLM277347734 | ||
| 035 | |a (NLM)29066514 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Canale, Fernando P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8+ T Cells |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.11.2018 | ||
| 500 | |a Date Revised 03.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Cancer Res. 2018 Sep 1;78(17):5173-5174. - PMID 30115699 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2017 American Association for Cancer Research. | ||
| 520 | |a The ability of CD8+ T lymphocytes to eliminate tumors is limited by their ability to engender an immunosuppressive microenvironment. Here we describe a subset of tumor-infiltrating CD8+ T cells marked by high expression of the immunosuppressive ATP ecto-nucleotidase CD39. The frequency of CD39highCD8+ T cells increased with tumor growth but was absent in lymphoid organs. Tumor-infiltrating CD8+ T cells with high CD39 expression exhibited features of exhaustion, such as reduced production of TNF and IL2 and expression of coinhibitory receptors. Exhausted CD39+CD8+ T cells from mice hydrolyzed extracellular ATP, confirming that CD39 is enzymatically active. Furthermore, exhausted CD39+CD8+ T cells inhibited IFNγ production by responder CD8+ T cells. In specimens from breast cancer and melanoma patients, CD39+CD8+ T cells were present within tumors and invaded or metastatic lymph nodes, but were barely detectable within noninvaded lymph nodes and absent in peripheral blood. These cells exhibited an exhausted phenotype with impaired production of IFNγ, TNF, IL2, and high expression of coinhibitory receptors. Although T-cell receptor engagement was sufficient to induce CD39 on human CD8+ T cells, exposure to IL6 and IL27 promoted CD39 expression on stimulated CD8+ T cells from human or murine sources. Our findings show how the tumor microenvironment drives the acquisition of CD39 as an immune regulatory molecule on CD8+ T cells, with implications for defining a biomarker of T-cell dysfunction and a target for immunotherapeutic intervention.Significance: The tumor microenvironment elicits a subset of functionally exhausted CD8+ T cells by creating conditions that induce cell surface expression of CD39, an immunosuppressive molecule that can be therapeutically targeted to restore effector T-cell function. Cancer Res; 78(1); 115-28. ©2017 AACR | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antigens, CD |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Adenosine Triphosphate |2 NLM | |
| 650 | 7 | |a 8L70Q75FXE |2 NLM | |
| 650 | 7 | |a Apyrase |2 NLM | |
| 650 | 7 | |a EC 3.6.1.5 |2 NLM | |
| 650 | 7 | |a CD39 antigen |2 NLM | |
| 650 | 7 | |a EC 3.6.1.5 |2 NLM | |
| 700 | 1 | |a Ramello, María C |e verfasserin |4 aut | |
| 700 | 1 | |a Núñez, Nicolás |e verfasserin |4 aut | |
| 700 | 1 | |a Araujo Furlan, Cintia L |e verfasserin |4 aut | |
| 700 | 1 | |a Bossio, Sabrina N |e verfasserin |4 aut | |
| 700 | 1 | |a Gorosito Serrán, Melisa |e verfasserin |4 aut | |
| 700 | 1 | |a Tosello Boari, Jimena |e verfasserin |4 aut | |
| 700 | 1 | |a Del Castillo, Andrés |e verfasserin |4 aut | |
| 700 | 1 | |a Ledesma, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Sedlik, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Piaggio, Eliane |e verfasserin |4 aut | |
| 700 | 1 | |a Gruppi, Adriana |e verfasserin |4 aut | |
| 700 | 1 | |a Acosta Rodríguez, Eva A |e verfasserin |4 aut | |
| 700 | 1 | |a Montes, Carolina L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer research |d 1945 |g 78(2018), 1 vom: 01. Jan., Seite 115-128 |w (DE-627)NLM000001740 |x 1538-7445 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2018 |g number:1 |g day:01 |g month:01 |g pages:115-128 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/0008-5472.CAN-16-2684 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2018 |e 1 |b 01 |c 01 |h 115-128 | ||